๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 22 Shanghai 21 Beijing 14 Wuhan 9 Hangzhou 7
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou22 Shanghai21 Beijing14 Wuhan9 Hangzhou7
All 31 locations
Target enrolment
to

Trials with a site in Guangzhou

22 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial
NCT07774754Rectal Cancer
Sun Yat-sen University
Phase 2
18
Guangzhou
2026-09-01
Recruiting
Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer
NCT07528209Rectal Cancer, pMMR (Microsatellite Stable Rectal Cancer)
DrugCapox
Sun Yat-sen University
Phase 3
556
Guangzhou
2026-04-20
Recruiting
Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Controlled Trial.
NCT07537998Low Anterior Resection Syndrome, Rectal Cancer
Pei-Rong Ding
Phase 2/3
160
Guangzhou
2026-04-10
Recruiting
A Study on the Accurate Evaluation of Pseudoprogression of Rectal Cancer Immunotherapy Based on Multitemporal and Multiparameter MRI
NCT07381322Rectal Cancer
Peiyi Xie
Observational
300
Guangzhou, Maoming
2026-02-01
Not yet open
SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer
NCT07297030Rectal Cancer
DrugCapox
Sun Yat-sen University
Phase 2
37
Guangzhou
2025-12-20
Recruiting
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
NCT06958432Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2/3
430
Guangzhou
2025-05-01
Recruiting
Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
NCT06923345Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
80
Guangzhou
2025-03-31
Recruiting
Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
NCT06719414Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
320
Guangzhou, Maoming
2024-10-22
Not yet open
Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer
NCT06255379Metastasis Colorectal Cancer, Colon Cancer, Rectal Cancer
Guangzhou University of Traditional Chinese Medicine
Phase 2
52
Guangzhou
2024-05-06
Recruiting
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy
NCT05965531Rectal Cancer
Sun Yat-sen University
Phase 2
65
Guangzhou
2024-01-01
Recruiting
Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients
NCT06043999Chemotherapy Effect, Rectal Cancer
Sun Yat-sen University
Not applicable
392
Guangzhou
2023-09-01
Recruiting
The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
NCT05984485Rectal Cancer
Sun Yat-sen University
Phase 3
766
Chongqing, Guangzhou, Hengyang, Shenyang, Xi'an, Nanchong
2022-07-05
Recruiting
Predicting the Efficacy of Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Using an AI Platform Based on Multi-parametric MRI
NCT05523245Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
1,700
Guangzhou, Zhuhai
2022-06-24
Active, closed
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
NCT05009069Rectal Neoplasms, Rectal Cancer
Hoffmann-La Roche
Phase 2
58
Beijing, Guangzhou, Hangzhou, Shanghai, Shenyang
2022-03-18
Recruiting
Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer
NCT05450029Rectal Cancer
Yanhong Deng
Phase 2
51
Guangzhou
2022-01-01
By invitation
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator
NCT05338866Rectal Cancer
Sun Yat-sen University
Observational
58
Guangzhou
2022-01-01
Recruiting
Targeted Optical Biopsy for Local Rectal Scars in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy
NCT05316103Rectal Cancer
Nanfang Hospital, Southern Medical University
Not applicable
68
Guangzhou
2021-11-04
Recruiting
Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer
NCT04643041Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
47
Guangzhou
2021-01-01
Recruiting
Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer
NCT04215731Rectal Cancer
Yanhong Deng
Phase 3
582
Guangzhou
2020-03-27
Active, closed
TNT to Increase the Clinical Complete Response Rate for Distal LARC
NCT03840239Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III, Chemoradiation
Sun Yat-sen University
Phase 2
98
Guangzhou
2018-12-25
Recruiting
Proximally Extended Resection for Rectal Cancer After Neoadjuvant Chemoradiotherapy
NCT02649647Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
240
Guangzhou
2016-02
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 22 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

16 of the 22 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 2 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 22 studies
PhaseStudiesRecruitingShare
Phase 28336.4%
Not applicable4418.2%
Observational4318.2%
Phase 34418.2%
Phase 2/3229.1%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Sun Yat-sen University95
Sixth Affiliated Hospital, Sun Yat-sen University66
Yanhong Deng22
Guangzhou University of Traditional Chinese Medicine10
Hoffmann-La Roche10
Nanfang Hospital, Southern Medical University11
Pei-Rong Ding11
Peiyi Xie11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.